Literature DB >> 26627481

Artesunate Protects Against Sepsis-Induced Lung Injury Via Heme Oxygenase-1 Modulation.

Tian-hui Cao1, Song-gen Jin2, Dong-sheng Fei2, Kai Kang2, Lei Jiang2, Zhi-yuan Lian2, Shang-ha Pan3, Ming-ran Zhao4, Ming-yan Zhao5.   

Abstract

Artesunate, a derivative of artemisinin, has anti-inflammatory properties and exerts protective roles in sepsis. Heme oxygense-1 (HO-1) inhibits the inflammatory response through reduction of proinflammatory cytokines and leukocyte influx into tissues. The present study investigated the effects of artesunate on HO-1 and septic lung injury. Cecal ligation and puncture (CLP) was employed to induce septic lung injury. Mice pretreated with artesunate (AS) (15 mg/kg) exhibited decreased sepsis-induced mortality and lung injury and alleviated lung pathological changes and neutrophil infiltration. In addition, AS lowered the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the serum and bronchoalveolar lavage fluid (BALF) and inhibited cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase isoform (iNOS) expression and NF-κB activation in lung tissue. In addition, AS enhanced NF-E2-related factor-2 (Nrf2) activation and HO-1 expression and enzymatic activity in lung tissue. However, the protective effects of AS on sepsis-induced lung injury were eliminated by ZnPP IX, an HO-1 competitive inhibitor. Therefore, AS plays protective roles in septic lung injury related to the upregulation of HO-1. These findings suggest an effective and applicable treatment to sepsis-induced lung injury and provide new insights into the molecular mechanisms and actions of AS.

Entities:  

Keywords:  acute lung injury; artesunate; heme oxgenase-1; sepsis

Mesh:

Substances:

Year:  2016        PMID: 26627481     DOI: 10.1007/s10753-015-0290-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  42 in total

1.  Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.

Authors:  Niels C Riedemann; Thomas A Neff; Ren-Feng Guo; Kurt D Bernacki; Ines J Laudes; J Vidya Sarma; John D Lambris; Peter A Ward
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

2.  Rho-kinase signaling regulates pulmonary infiltration of neutrophils in abdominal sepsis via attenuation of CXC chemokine formation and Mac-1 expression on neutrophils.

Authors:  Zirak Hasan; Karzan Palani; Milladur Rahman; Su Zhang; Ingvar Syk; Bengt Jeppsson; Henrik Thorlacius
Journal:  Shock       Date:  2012-03       Impact factor: 3.454

3.  Induction of cyclooxygenase-2 in alveolar macrophages after acid aspiration: selective cyclooxygenase-2 blockade reduces interleukin-6 production.

Authors:  M Ohara; T Sawa; K Kurahashi; J P Wiener-Kronish; V Doshi; I Kudoh; M A Gropper
Journal:  Anesthesiology       Date:  1998-04       Impact factor: 7.892

Review 4.  Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.

Authors:  Y J Surh; K S Chun; H H Cha; S S Han; Y S Keum; K K Park; S S Lee
Journal:  Mutat Res       Date:  2001-09-01       Impact factor: 2.433

5.  Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo.

Authors:  N Futaki; S Takahashi; T Kitagawa; Y Yamakawa; M Tanaka; S Higuchi
Journal:  Inflamm Res       Date:  1997-12       Impact factor: 4.575

6.  Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin.

Authors:  Weiwei Jiang; Bin Li; Xinchuan Zheng; Xin Liu; Yanyan Cen; Jun Li; Xichun Pan; Hongwei Cao; Jiang Zheng; Hong Zhou
Journal:  Int Immunopharmacol       Date:  2011-03-21       Impact factor: 4.932

7.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Hemin inhibits NLRP3 inflammasome activation in sepsis-induced acute lung injury, involving heme oxygenase-1.

Authors:  Yun-peng Luo; Lei Jiang; Kai Kang; Dong-sheng Fei; Xiang-lin Meng; Chuan-chuan Nan; Shang-ha Pan; Ming-ran Zhao; Ming-yan Zhao
Journal:  Int Immunopharmacol       Date:  2014-02-26       Impact factor: 4.932

9.  Cyclooxygenase-2-deficient mice are resistant to endotoxin-induced inflammation and death.

Authors:  Kuniaki Ejima; Matthew D Layne; Irvith M Carvajal; Patricia A Kritek; Rebecca M Baron; Yen-Hsu Chen; Jeffrey Vom Saal; Bruce D Levy; Shaw-Fang Yet; Mark A Perrella
Journal:  FASEB J       Date:  2003-05-08       Impact factor: 5.191

10.  Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.

Authors:  Bin Li; Rong Zhang; Jun Li; Lezhi Zhang; Guofu Ding; Ping Luo; Shengqi He; Yan Dong; Weiwei Jiang; Yongling Lu; Hongwei Cao; Jiang Zheng; Hong Zhou
Journal:  Int Immunopharmacol       Date:  2007-12-07       Impact factor: 4.932

View more
  19 in total

1.  Artesunate Inhibits Renal Ischemia-Reperfusion-Mediated Remote Lung Inflammation Through Attenuating ROS-Induced Activation of NLRP3 Inflammasome.

Authors:  Zhaohui Liu; Min Qu; Lili Yu; Panpan Song; Yulin Chang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

2.  Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway.

Authors:  Zhaohui Liu; Junjie Zhang; Shitong Li; Jihong Jiang
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

3.  The Antimalaria Drug Artesunate Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication by Activating AMPK and Nrf2/HO-1 Signaling Pathways.

Authors:  Feixiang Long; Mingxin Zhang; Xia Yang; Xiaohuan Liang; Lizhan Su; Tongqing An; Guihong Zhang; Zhenling Zeng; Yahong Liu; Weisan Chen; Jianxin Chen
Journal:  J Virol       Date:  2021-11-17       Impact factor: 6.549

4.  Effect of Heme Oxygenase-1 on Mitofusin-1 protein in LPS-induced ALI/ARDS in rats.

Authors:  Jianbo Yu; Ying Wang; Zhen Li; Shuan Dong; Dan Wang; Lirong Gong; Jia Shi; Yuan Zhang; Daquan Liu; Rui Mu
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

5.  Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.

Authors:  Jong-Lyel Roh; Eun Hye Kim; Hyejin Jang; Daiha Shin
Journal:  Redox Biol       Date:  2016-12-18       Impact factor: 11.799

6.  Epidermal Growth Factor, through Alleviating Oxidative Stress, Protect IPEC-J2 Cells from Lipopolysaccharides-Induced Apoptosis.

Authors:  Xiaopeng Tang; Bo Liu; Xiangrong Wang; Qifang Yu; Rejun Fang
Journal:  Int J Mol Sci       Date:  2018-03-14       Impact factor: 5.923

Review 7.  Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.

Authors:  Dorothy H J Cheong; Daniel W S Tan; Fred W S Wong; Thai Tran
Journal:  Pharmacol Res       Date:  2020-05-13       Impact factor: 7.658

8.  DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-Induced Arthritis Through an Nrf2-p62-Keap1 Feedback Loop.

Authors:  Menglin Fan; Yanan Li; Chunhua Yao; Xiufeng Liu; Jihua Liu; Boyang Yu
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

Review 9.  Could Heme Oxygenase-1 Be a New Target for Therapeutic Intervention in Malaria-Associated Acute Lung Injury/Acute Respiratory Distress Syndrome?

Authors:  Marcelo L M Pereira; Claudio R F Marinho; Sabrina Epiphanio
Journal:  Front Cell Infect Microbiol       Date:  2018-05-16       Impact factor: 5.293

Review 10.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.

Authors:  Yujun Tang; Jiajia Liu; Dingyi Zhang; Zhenghao Xu; Jinjun Ji; Chengping Wen
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.